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ABSTRACT: The overexpression of vascular endothelial growth
factor (VEGF) in varying types of solid tumor renders radio-
immunotherapy (RIT) with the anti-VEGF antibody bevacizumab
(BV) a promising treatment. However, the slow blood clearance of
BV, which may increase the occurrence risk of hematotoxicity, hinders
the application of BV-RIT. Using the avidin chase is a long-known
blood clearance enhancement strategy for biotinylated-mAb. To
enhance RIT eﬃcacy by increasing the radioactivity dose, we
evaluated the ability of avidin to accelerate the blood clearance of
yttrium-90 (90Y)-labeled biotinylated BV (90Y-Bt-BV) in a xenograft
mouse model of triple-negative breast cancer (TNBC). The biodistribution study in the TNBC xenograft mice conﬁrmed the
high and speciﬁc tumor accumulation of the indium-111 (111In)-BV. The blood clearance enhancement eﬀect of the avidin chase
was demonstrated in the normal mouse studies with 111In-Bt-BV. In the subsequent biodistribution studies with the tumor-
bearing mice, an optimized dose of avidin injection subsequent to 111In-Bt-BV with an appropriate biotin valency successfully
accelerated the blood clearance of 111In-Bt-BV without impairing its tumor accumulation level. The avidin chase enabled an
increase in the maximum tolerated dose of 90Y-Bt-BV to twice as much as that of 90Y−BV in tumor-bearing mice and thereby
signiﬁcantly improved the therapeutic eﬀect of 90Y-Bt-BV compared to 90Y−BV (p < 0.05). These results underscored the
potential usefulness of 90Y-bevacizumab-RIT with the avidin chase for the treatment of VEGF-positive tumors.
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■ INTRODUCTION
With the outstanding achievements of radiolabeled monoclonal
antibodies (mAbs) in treating hematological malignancies,
interest in radioimmunotherapy (RIT) has grown as an
attractive approach for solid tumors.1,2 As the carrier of
radionuclides in RIT, the prerequisite for mAbs is high tumor-
targeting speciﬁcity and aﬃnity rather than the antitumor eﬀect
itself. This means that mAbs against many types of tumor-
associated antigens can be potential candidates for RIT. A
promising target is vascular endothelial growth factor (VEGF),
one of the hallmarks of cancer.3,4 Although VEGF is a secreted
protein, it is retained in the tumor tissue, and thus the
preclinical as well as clinical success of radiolabeled
bevacizumab (a clinically used anti-VEGF antibody) in
radioimmunoimaging and RIT has been reported.5−9 Consid-
ering wide application of bevacizumab for substantial kinds of
cancer,10,11 clinical use of bevacizumab-RIT is awaited.
However, in contrast to the high eﬀectiveness of RIT in
hematological malignancies, the clinical success of RIT for solid
tumors is modest. This is due mainly to the relationship
between the therapeutic eﬀect and hematotoxicity.2 The large
molecular size of the IgGs, that is, 150 kDa, prolongs their
circulation time and thus increase the risk of hematopoietic and
other normal organ toxicity.12 Because bevacizumab has an
even longer terminal biological half-life compared to other
mAbs (approximately 20 days, range 11−50 days in
patients),13,14 a blood clearance enhancement strategy is
necessary for the application of bevacizumab RIT in clinical
settings.
Currently, blood clearance enhancement approaches rely on
the smaller molecular sizes of radiolabeled compounds.12,15,16
While the use of fragmented antibodies eﬀectively enhances
blood clearance compared to IgG, the advantage of these
antibodies is limited because their simultaneously decreased
tumor accumulation level compromises the therapeutic eﬀect.
In a pretargeting strategy, by contrast, the high radioactivity
level in the tumor is maintained because the tumor is preloaded
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with nonradiolabeled antibodies, and subsequently, antibody-
reactive radiolabeled small molecules are delivered.17,18 The
radioactivity level in the tumor relies on the uptake level of
nonradiolabeled mAbs, whereas the blood clearance rate
depends on the rapid elimination pattern of the radiolabeled
small molecule. However, if an antibody has an extremely slow
blood clearance rate, an additional step, the injection of a
‘clearing agent’, is necessary.17,19 If antibodies remain in the
circulation, they prevent radiolabeled small molecules from
binding to the antibodies located in the tumor by trapping the
radiolabeled small molecules in the circulation. Therefore, it is
desirable to develop a more simple and eﬀective strategy as an
alternative to this complex and troublesome three-step
pretargeting RIT.
Another eﬀective strategy for increasing therapeutic index by
reducing hematopoietic toxicity is the removal of radiolabeled
antibody from circulation such as “chase” and extracorporeal
depletion.20,21 In the chase strategy, molecules directly
recognize radiolabeled antibody such as secondary antibody
or avidin for biotinylated antibody are injected.20,22 Studies in
tumor bearing mice reported the dramatic decrease in the
blood radioactivity following avidin chase.20,23−25 However,
while a number of pretargeting RIT studies harnessing avidin−
biotin system, avidin chase strategy for RIT has rarely been
performed. No study applied the avidin chase strategy for RIT
with yttrium-90 (90Y)-labeled antibody. Nevertheless, avidin
chase would exert powerful eﬀect for antibodies with slow
clearance rate like bevacizumab. In this study, we performed
therapeutic studies of 90Y-labeled biotinylated bevacizumab
(90Y-Bt-BV), followed by avidin chase in a xenograft model of
triple-negative breast cancer (TNBC), which is a bevacizumab-
avid and notoriously refractory type of tumor.26,27 We
evaluated the utility of avidin chase for accelerating the blood
clearance of 90Y-Bt-BV, and we assessed the potential of the
strategy to enhance the eﬃcacy of RIT by increasing the
radioactivity dose.
■ MATERIALS AND METHODS
Conjugation and Radiolabeling of Monoclonal Anti-
bodies. Bevacizumab (BV) was purchased from Chugai
Pharmaceutical (Tokyo), and a murine anti-CD20 mAb,
NuB2, was purchased from Immuno-Biological Laboratories
(Fujioka, Japan). We used 2-(4-isothiocyanatobenzyl)-dieth-
ylenetriaminepentaacetic acid (SCN-Bn-DTPA; Macrocyclics,
Dallas, TX) for the indium-111 (111In) or 90Y labeling of the
mAbs. Typically, SCN-Bn-DTPA in dimethylformamide was
added to mAb (5 mg/mL in 50 mM borate-buﬀered saline, pH
8.5) at the molar ratio of 5:1 and incubated for 24 h at 37 °C.
The DTPA-mAbs were puriﬁed using a Bio-Spin column (Bio-
Rad Laboratories, Hercules, CA) eluted with phosphate-
buﬀered saline (PBS). The number of DTPA attached per
molecule of mAb was determined as 1.1, according to the
procedure described previously.28
The biotinylated-DTPA-BV (DTPA-Bt-BV) was prepared by
conjugation of 6-[6-(biotinylamino)hexanoylamino]hexanoic
acid N-hydroxysuccinimide ester (Dojindo, Kumamoto,
Japan) with amine group of antibody in 0.1 M borate buﬀer
(pH 8.5) at the molar ratio of 3:1, 6:1, or 10:1 overnight at 37
°C. The DTPA-Bt-BV was puriﬁed as described above.
The average number of biotin molecules per mAb was
determined by performing a 4′-hydroxyazobenzene-2-carbox-
ylic acid (HABA) assay.29 The mixture of HABA (1.4 mg/
mL)/avidin (2.5 mg/mL) in 10 μL of phosphate buﬀer was
added with 5 μL of phosphate buﬀer solution of DTPA-Bt-BVs.
After a 5 min incubation, the absorbance at 500 nm was
measured with a spectrophotometer (NanoDrop ND-1000,
ThermoFisher Scientiﬁc, Waltham, MA). The biotin concen-
tration of each DTPA-Bt-BV was calculated in a comparison
with a standard curve using the absorbance of the mixtures with
a known concentration of biotin. The protein concentration
was also determined based on the absorbance at 280 nm, and
then the biotin valencies (biotin number per mAb) were
calculated based on the ratio of molar concentrations. The
reaction of biotin and DTPA-BV at the molar ratio of 3:1, 6:1,
and 10:1 resulted in the biotin valencies of 2.0, 3.5 ± 0.5 (n =
3), and 7.1, respectively (hereinafter referred to as DTPA-Bt2.0-
BV, DTPA-Bt3.5-BV, and DTPA-Bt7.1-BV, respectively).
Radiolabeling of Monoclonal Antibodies. For the
preparation of the 111In- or 90Y-labeled mAbs, 40 μL (0.37−
1.85 MBq) of 111InCl3 solution (Nihon Medi-Physics, Tokyo)
or 20−60 μL (74−296 MBq) of 90YCl3 solution (Nucleic,
Braunschweig, Germany) was incubated in 0.25 M acetate
buﬀer (pH 5.5, 60, or 200 μL, respectively) for 5 min at room
temperature, followed by incubation with DTPA-mAbs (10 μg
or 200−800 μg in 0.1 M phosphate buﬀer, respectively) for 1 h
at 37 °C. To trap unconjugated radiometals, 3−5 μL of 100
mM EDTA was added to the reaction mixture.
Iodine-125-labeled BV was prepared according to the
standard protocols for the chloramine-T method30 with slight
modiﬁcation. Brieﬂy, 3.7 MBq/2 μL of Na125I (PerkinElmer,
Waltham, MA) and 1 μg of chloramine-T in 1 μL of 0.3 M
phosphate buﬀer (pH 7.4) were added to 40 μg of antibody in
100 μL of 0.3 M phosphate buﬀer and incubated for 10 min at
room temperature. The radiolabeled mAbs were puriﬁed as
described above. For the puriﬁcation of 90Y-labeled mAbs, a
PD-10 column (GE Healthcare Biosciences AB, Piscataway,
NJ) was used instead of the Biospin column. The radiochemical
purity of all radiolabeled mAbs after puriﬁcation was >95%,
determined based on the results of Tec-Control Chromatog-
raphy Strips (Biodex Medical Systems, Shirley, NY). In case of
111In- or 90Y-labeled mAbs, 3 μL of 100 mM EDTA was added
to the reaction mixture to trap unconjugated radiometals. One
drop of the reaction mixture was spotted on the strip, then the
strip was developed with saline. Rf values of radiolabeled
antibody and free 125I, 111In-EDTA, or 90Y-EDTA were 0 and 1,
respectively. The radiochemical yield of 111In-labeled BV, 90Y-
labeled BV, and 125I-labeled BV were >90% (n > 10), 88.8 ±
9.1% (n = 5, mean ± SD), and 87.0%, respectively. The speciﬁc
radioactivity of the puriﬁed 111In-labeled BV, 90Y-labeled BV,
and 125I-labeled BV were 37−185 MBq/mg mAb, 290−520
MBq/mg mAb, and 64.4 MBq/mg mAb, respectively.
Immunoreactivity Evaluation. Recombinant human
VEGF165 was purchased from HumanZyme (Chicago, IL).
The VEGF165-coated 96-well plate was prepared as described
by Chang et al.31 with slight modiﬁcation (VEGF165
concentration of 3 μg/μL). A mixture of 125I−BV (0.5 kBq/
0.001 μg) and serial amounts of unlabeled DTPA-BV, DTPA-
Bt2.0-BV, DTPA-Bt3.5-BV, or DTPA-Bt7.1-BV (0.01−100 μg)
were added to each well and incubated for 2 h at room
temperature. The wells were then washed with 200 μL of PBS
three times, and the radioactivity of each well was counted
using a well-type gamma counter (ARC7001; Hitachi Aloka
Medical, Tokyo).
Tumor Xenograft Mouse Model Preparation. All
animal experiments were approved by the animal experiments
committee of Gunma University. The TNBC cell line with high
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VEGF expression level, MDA-MB-231,32 was purchased from
American Type Culture Collection (Manassas, VA). The
cultured cell was harvested and suspended in a mixture of
PBS and Matrigel (Corning Life Sciences, Corning, NY) at a
1:1 (v/v) ratio. The cell suspension (5 × 106 cells/100 μL/
mice) was injected into the right dorsal ﬂank of 6-week-old
female BALB/c nude mice (Japan SLC, Shizuoka, Japan). The
tumor volume was measured twice a week with a caliper, and
the tumor volume was calculated as tumor volume = 1/2
(length × width2). The mice were used for the biodistribution
studies or therapeutic studies when the tumor volume reached
150−250 mm3.
Immunohistochemistry. The expression levels of VEGF
in the MDA-MB-231 xenograft tumor was analyzed by
immunohistochemical staining. Tumor xenografts excised
from nude mice were embedded in O.C.T. compound (Sakura
Finetek Japan, Tokyo) and frozen at −80 °C. Cryosections (6-
μm) were immunostained with a rabbit anti-VEGF-A primary
antibody (ab46154, Abcam, Cambridge, UK). Immunostaining
was detected with a mouse antirabbit secondary antibody (IgG-
PerCP: sc-45098, Santa Cruz Biotechnology, Dallas, TX). The
sections were counterstained with hematoxylin solution.
Negative controls were obtained by omitting the primary
antibody.
Biodistribution Studies. We performed four types of
biodistribution studies in either tumor xenograft mice or
normal ddY mice (Japan SLC) with 111In-labeled mAbs as a
surrogate for 90Y-labeled mAbs.33,34 All mice were fed with
normal diet (contains 27 μg of biotin/100 g of pellet). A
summary of biodistribution studies is provided as Figure 1. In
all studies, radiolabeled antibody and avidin were injected
intravenously via tail vein. The tissues of interest were dissected
out and weighed at the indicated time after tracer injection, and
then the radioactivity was measured by a well-type gamma
counter. The accumulation of the tracers is expressed as a
percentage of the injected dose per gram of tissue. Radiation-
eﬀective doses for humans were calculated from the
biodistribution data of tumor-bearing mice using the software
program OLINDA/EXM (version 1.1; Vanderbilt University,
Nashville, TN).35
Study 1: Evaluation of Biodistribution Proﬁles and Tumor
Speciﬁcity of 111In−BV in MDA-MB-231 Tumor Xenograft
Mice. One-hundred microliters of 111In-labeled DTPA-BV
(111In−BV, 20 kBq/20 μg of mAb) was injected into the
tumor-bearing mice. Radioactivity uptakes were determined at
1, 24, 72, and 168 h after injection. To evaluate the speciﬁcity of
111In−BV to the xenograft tumor, we injected the mice with
111In-DTPA-BV in the presence of unlabeled antibody (20, 100,
or 500 μg/mouse) and sacriﬁced at 72 h after injection. The
radioactivity uptake of 111In-DTPA-NuB2 was also evaluated at
1, 24, and 72 h after injection of 100 μL aliquot of 111In-DTPA-
NuB2 (20 kBq/20 μg of mAb).
Study 2: Eﬀect of Biotin Valency and Clearing Agent
Injection on Biodistribution Proﬁles of 111In-Bt(n)-BV. We
evaluated the biodistribution proﬁles of 111In-labeled DTPA-
Bt(n)-BV (111In-Bt2.0-BV,
111In-Bt3.5-BV, or
111In-Bt7.1-BV) in
normal ddY mice at 24 h after injection of 100 μL each aliquot
(20 kBq/20 μg of mAb). To evaluate whether avidin could
accelerate the blood clearance of 111In-Bt(n)-BV, we injected
100 μL of avidin solution (9.0 μg/mouse, molar equivalent [eq]
to that of BV; Wako Pure Chemical Industries, Osaka, Japan) at
24 h after 111In-Bt(n)-BV administration. Radioactivity uptakes
were determined at 3 h after avidin injection, that is, 27 h after
111In-Bt(n)-BV injection.
Study 3: Eﬀect of Avidin Dose on Biodistribution Proﬁles
of 111In-Bt3.5-BV. Normal mice were injected with 100 μL
solution of 111In-Bt3.5-BV (20 kBq/20 μg of mAb), and 24 h
later, the mice were injected with serial amounts of avidin (0, 1/
5, 1/2, 1, 2, 5 eq of BV). Radioactivity uptakes were evaluated
at 3 h after the injection of avidin, that is, at 27 h after the 111In-
Bt3.5-BV injection.
Study 4: Comparison of Biodistribution Proﬁles of 111In−
BV and 111In-Bt3.5-BV in Tumor Xenograft Mice. One-hundred
microliters of 111In−BV or 111In-Bt3.5-BV (20 kBq/20 μg of
mAb) was injected into the tumor-bearing mice, and radio-
activity uptakes were determined at 27 and 72 h postinjection.
For the 111In-Bt3.5-BV group, 100 μL of avidin solution (9.0 μg/
mouse, 1 eq of BV) was injected at 24 h after the 111In-Bt3.5-
BV administration.
Dose Escalation Studies of 90Y-Bt3.5-BV and
90Y−BV.
To determine the inﬂuence of avidin on the maximum tolerated
dose (MTD) of 90Y-labeled DTPA-Bt3.5-BV (
90Y-Bt3.5-BV), we
performed escalating radioactivity dose studies of 90Y-Bt3.5-BV
with avidin injection in normal mice (7.4−18.5 MBq/100−250
μL/mouse) and tumor-bearing mice (3.7−9.25 MBq/100−250
μL/mouse) in a comparison with 90Y-labeled DTPA-BV (90Y−
BV). Avidin was intravenously injected at 24 h after the 90Y-
Bt3.5-BV administration. The body weight of each mouse was
monitored twice a week. The MTD was determined based on
the death of mice or body weight loss exceeding 20%.
Therapeutic Study. When the tumors were fully
established (200 ± 71 mm3), we divided the mice into three
groups (n = 8 per group). Group 1: Treated with 90Y-Bt3.5-BV
(7.4 MBq/100 μL/mouse) followed by 1 eq. of avidin injection
at 24 h postinjection. Group 2: Treated with 90Y−BV (3.7
MBq/100 μL/mouse). Group 3: Untreated (control group).
There was no signiﬁcant diﬀerence in the initial tumor volume
among the groups. The tumor volumes were determined twice
Figure 1. Summary of the biodistribution studies performed with
111In-labeled mAbs. Study 1: Evaluation of biodistribution proﬁles and
tumor speciﬁcity of 111In−BV in MDA-MB-231 tumor xenograft mice.
Study 2: Eﬀect of biotin valency and clearing agent injection on the
biodistribution proﬁles of 111In-Bt(n)-BV in normal mice. Study 3:
Eﬀect of avidin dose on the biodistribution proﬁles of 111In-Bt3.5-BV in
normal mice. Study 4: Comparison of the biodistribution proﬁles of
111In−BV and 111In-Bt3.5-BV in tumor xenograft mice.
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a week as described above. The observation was terminated
when the tumor volume exceeded 2000 mm3 or the mice were
dead.
Statistical Analysis. Data are expressed as mean ±
standard deviation (SD). For the comparison of the data of
pairs of groups, Student’s t-test was used. P-values < 0.05 were
considered signiﬁcant. GraphPad Prism software ver. 7
(GraphPad Software, La Jolla, CA) was used.
■ RESULTS
Analysis of Bt-BVs. The DTPA conjugation and biotin
valencies (biotin number per mAb) of DTPA-Bt-BV (2.0−7.1)
did not aﬀect the binding aﬃnity of BV to VEGF165, as the
immunoreactivity assay conﬁrmed their maintained speciﬁcity
(Figure 2).
Biodistribution Study. The biodistribution Study 1
demonstrated a high and speciﬁc tumor accumulation of the
radiolabeled BV in the TNBC xenograft tumors. In the tumor-
bearing mice, high tumor accumulation and retention of 111In−
BV were noted (Figure 3). The tumor uptake was signiﬁcantly
suppressed in the presence of the excess amount of unlabeled
antibody (Figure S1, p < 0.05). The immunohistochemical
analysis revealed the high expression level of VEGF in the
MDA-MB-231 tumors (Figure S2). By contrast, 111In-labeled
anti-CD20 antibody showed signiﬁcantly lower tumor accu-
mulation compared to 111In−BV at 24 and 72 h after injection
(Figure S3, p < 0.05). The biodistribution Study 1 also showed
the high blood radioactivity levels of 111In−BV even at 72 and
168 h after injection (Figure 3A, 16.7 ± 2.1 and 14.0 ± 3.6%
ID/g, respectively) due to its slow blood clearance.
To determine whether the clearing agent injection could
improve the slow blood clearance rate of BV, we next explored
the inﬂuence of biotin valencies on the biodistribution patterns
of 111In-Bt(n)-BV in normal mice (Study 2). At 24 h after
injection, the blood radioactivity levels of 111In-Bt2.0-BV and
111In-Bt3.5-BV were comparable to that of
111In−BV, whereas
that of 111In-Bt7.1-BV was signiﬁcantly low (Figure 4A, p <
0.01). When avidin was injected subsequently to the tracers, the
blood radioactivity level of 111In-Bt3.5-BV became signiﬁcantly
lower than that of 111In−BV (Figure 4B, p < 0.01), whereas that
of 111In-Bt2.0-BV remain unaﬀected.
We then explored the inﬂuence of the amount of avidin on
the blood clearance enhancement of 111In-Bt3.5-BV (Study 3).
Avidin decreased the blood radioactivity levels of 111In-Bt3.5-BV
in a dose-dependent manner, but there was no signiﬁcant
diﬀerence between the levels of the 1 eq, 2 eq, and 5 eq groups
(Figure 4C). On the basis of these results, we used the
combination of 111In-Bt3.5-BV with 1 eq of avidin injection in
the following biodistribution and therapeutic studies.
Figure 2. Immunoreactivity evaluation using VEGF165-coated 96-well plates. Each value is the mean ± SD (n = 4).
Figure 3. Biodistribution of radioactivity after the injection of 111In−BV (protein dose: 20 μg) in the tumor-bearing mice. The biodistribution study
data are mean ± SD (n > 4).
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This combination also accelerated the blood clearance of
111In-Bt3.5-BV in the MDA-MB-231 xenograft mice (Figure 5).
At 27 h after injection, the radioactivity level in the blood of the
111In-Bt3.5-BV group was signiﬁcantly lower than that of the
Figure 4. Biodistribution of the radioactivity of 111In−BV or 111In-Bt(n)-BV with avidin in normal mice. (A) 24 h after the injection of 111In−BV or
111In-Bt(n)-BV (mean ± SD, n > 3). Signiﬁcant diﬀerences were observed between 111In-Bt(n)-BV and 111In−BV (∗p < 0.05, #p < 0.01). (B) 27 h
after the injection of 111In−BV or 111In-Bt(n)-BV with 1 eq of avidin (mean ± SD, n > 3). Signiﬁcant diﬀerences were observed between 111In-Bt(n)-
BV and 111In−BV (∗p < 0.05, #p < 0.01). (C) 27 h after injection of 111In-Bt3.5-BV with increasing amount of avidin (mean ± SD, n > 3). Avidin
injection signiﬁcantly decreased the blood radioactivity levels and increased the liver and spleen radioactivity levels (∗p < 0.05, #p < 0.01).
Figure 5. Biodistribution of radioactivity 27 and 72 h after the injection of 111In−BV or 111In-Bt3.5-BV with 1 eq of avidin (mean ± SD, n > 3). The
blood radioactivity levels of the 111In-Bt3.5-BV group were signiﬁcantly lower than those of the
111In−BV group (∗p < 0.05, #p < 0.01). There was no
signiﬁcant diﬀerence in tumor accumulation levels between the 111In-Bt3.5-BV group and
111In−BV group.
Table 1. Escalating Radioactivity Dose Studies of 90Y-Bt3.5-BV with Avidin Injection and
90Y−BV in Normal Mice and Tumor-
Bearing Micea
dose/mouse (MBq) 3.7 5.55 7.4 9.25 11.1 12.95 14.8 16.65 18.5
normal mice 90Y−BV −c − 4/4 4/4b 3/4 1/4 − − −
90Y-Bt3.5-BV − − − 4/4 4/4b 2/4 1/4 0/4 0/2
tumor-bearing mice 90Y−BV 5/5b 3/5 1/4 − − − − − −
90Y-Bt3.5-BV 3/3 3/3 3/3
b 0/3 − − − − −
aEach value represents the number of survived mice/total mice at each dose. bMTD was determined as the highest dose at which no mice died. c−:
not tested.
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111In−BV group (11.1 ± 4.4%dose/g vs 25.4 ± 3.4%dose/g,
respectively, p < 0.01). No signiﬁcant diﬀerence was observed
in tumor radioactivity levels between the 111In-Bt3.5-BV group
and 111In−BV group (9.9 ± 2.4%dose/g and 10.7 ± 0.5%dose/
g, respectively). The tumor to blood ratio of 111In-Bt3.5-BV
group became higher than that of 111In−BV group (1.10 ± 0.73
vs 0.43 ± 0.04, respectively) though the diﬀerence was not
statistically signiﬁcant. The avidin injection signiﬁcantly raised
the radioactivity levels in the liver (17.2 ± 3.5%dose/g and 5.9
± 0.4%dose/g, respectively, p < 0.01).
The eﬀective dose of 90Y−BV and 90Y-Bt3.5-BV estimated
from biodistribution data was 0.797 and 0.753 mSv/MBq,
respectively. The estimated absorbed dose of 90Y−BV and 90Y-
Bt3.5-BV to the red marrow was 0.197 and 0.125 mSv/MBq,
respectively, and that to the liver was 1.27 and 1.74 mSv/MBq,
respectively.
Therapeutic Study. The escalating radioactivity dose studies
revealed that the avidin injection could widen the applicable
range of 90Y-Bt3.5-BV. In both the normal mice and the tumor-
bearing mice, the MTD of 90Y-Bt3.5-BV with the avidin injection
was higher than that of 90Y−BV (11.1 MBq vs 9.25 MBq in the
normal mice, and 7.4 MBq vs 3.7 MBq in the tumor-bearing
mice, respectively, Table 1). Therefore, in the subsequent
therapeutic study, we administered 7.4 MBq of 90Y-Bt3.5-BV or
3.7 MBq of 90Y−BV to the mice in each group. Tumor growth
was signiﬁcantly suppressed in both treatment groups
compared to that of the control group (Figure 6, p < 0.01).
In particular, the tumor volume of group 1 (90Y-Bt3.5-BV with
avidin) was signiﬁcantly smaller than that of group 2 (90Y−BV)
at 22, 26, and 29 days after treatment (p < 0.05, Figure 6). Two
of the eight mice in group 1 and one of the eight mice in group
2 died approximately 3 weeks after treatment.
■ DISCUSSION
The high and persistent accumulation of 111In−BV observed in
the VEGF-positive TNBC tumor (MDA-MB-231) xenograft
supports RIT with BV as an attractive candidate for TNBC
treatment, though the indication of unlabeled BV for breast
cancer was withdrawn by the U.S. Food and Drug
Administration (FDA) in 2011 based on the lack of overall
survival improvement.26,36 At the same time, the slow blood
clearance of 111In−BV, which is consistent with previous
studies,5,13 conﬁrmed the necessity of a blood clearance
enhancement strategy.
The present normal mice studies demonstrated that the
avidin chase worked eﬃciently to enhance the blood clearance
of 111In−BV, and an appropriate biotin valency is a responsible
factor for the success of the avidin chase. All Bt-BVs maintained
the binding aﬃnity to VEGF165, whereas seven-biotin
functionalization (111In-Bt7.1-BV) greatly altered the biodis-
tribution pattern of 111In−BV. Khawli et al. suspected that the
reduced net charge of antibody by biotinylation of ε-amino
groups of lysine residues is the factor responsible for the
enhanced blood clearance.37 As the number of biotins increases,
111In-Bt-BVs would have become more susceptible to being
recognized as a foreign substance since the accumulation level
of 111In-Bt-BVs in the liver, kidney, and spleen became higher
with the increase in the number of biotins. The use of Bt7.1-BV
as an RIT agent thus would be inappropriate since increased
oﬀ-target distribution inevitably decreases the tumor accumu-
lation level. Too small a biotin valency is, by contrast, also
inappropriate. Although the avidin injection in the present
study decreased the blood radioactivity level of 111In-Bt3.5-BV, it
did not aﬀect the blood radioactivity level of 111In-Bt2.0-BV.
This is presumably because a certain number of biotin
functionalization was necessary to eﬀectively eliminate BV
from the systemic circulation by enabling the avidin(s) to
readily conjugate with each BV molecule.
The optimized dose of avidin injection successfully
accelerated the blood clearance of 111In-Bt3.5-BV without
impairing its tumor accumulation level. The equivalent amount
of avidin to Bt3.5-BV turned out to be suﬃcient to suppress the
blood radioactivity level in the normal mice study. This is
excessive (by four-times) compared to the amount of Bt3.5-BV
that remained in the circulation at 24 h after injection,
considering the blood radioactivity levels of 111In-Bt3.5-BV
(approximately 25% dose, assuming that the blood volume of
mice is 2 mL). This result was inconsistent with previous
observation that reported more than 10-times excess amount of
avidin injection does-dependently accelerate the blood
clearance of radiolabeled biotinylated antibodies.20,38 The
discrepancy may be due to the diﬀerence in the nature of
antibodies, biotin valencies, or radiolabeling method used in
these studies. We ﬁnally selected 1 eq of avidin since the
Figure 6. Therapeutic eﬀect of 90Y−BV or 90Y-Bt3.5-BV in tumor-bearing mice (mean ± SD, n > 6). Tumor growth was signiﬁcantly inhibited in both
the 90Y−BV- and 90Y-Bt3.5-BV-treated mice compared to the untreated control mice (#p < 0.01). The tumor volume of the 90Y-Bt3.5-BV group was
signiﬁcantly smaller than that of the 90Y−BV group from day 22 to day 29 (∗p < 0.05).
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.8b00027
Mol. Pharmaceutics XXXX, XXX, XXX−XXX
F
necessary suﬃcient amount should be used to avoid the
possibility that surplus avidin may bind and remove the
antibodies already accumulated in the tumor. Further reduction
in the blood radioactivity level was not observed at 3 h after the
avidin injection (up to 24 h, data not shown) as previously
reported, probably because avidin itself was rapidly eliminated
from the circulation.19,25
The accelerated blood clearance by avidin chase successfully
minimized the radiation exposure to bone marrow, the dose-
limiting organ. The lowered estimated absorbed dose to the red
marrow in the avidin chase group (0.197 vs 0.125 mSv/MBq)
indicates the increased therapeutic index in those mice 1.5-
times more than mice without avidin chase. The accelerated
blood clearance instead increased the radioactivity level
accumulated in the liver. The clearance rate from the liver
was much slower than what has been reported for radioiodine
labeled antibodies due to the residualizing nature of radio-
metal.39 One concern regarding increased radioactivity
accumulation is the liver toxicity. However, the estimated
absorbed dose to the liver was increased by only 1.37-times
between mice with or without avidin chase and thus would be
acceptable. When 3.75-times higher dose 90Y-ibritumomab
tiuxetan RIT with autologous stem cell transplantation was
applied, no liver toxicity developed in the patient who received
a dose of 25 Gy to the liver, the dose limiting organ in their
study.40
As expected, the avidin injection enabled the increase in the
MTD of 90Y-Bt3.5-BV to twice as much as that of
90Y−BV in
tumor-bearing mice, which consequently improved the
therapeutic eﬀect of 90Y-Bt3.5-BV by increasing the absorbed
dose to the tumor. To our knowledge, this is the ﬁrst study that
demonstrated the usefulness of avidin chase for increasing the
MTD and dramatically potentiating the therapeutic eﬀect of
90Y−BV. The avidin chase strategy has yet to be applied in
clinic, but it is worth investigating the potential eﬀect for tumor
treatment in future clinical studies. Further studies using
various solid tumor models are desirable to conﬁrm the
applicability of this strategy. Even though the tumors were not
completely eradicated, the avidin chase strategy is simple
compared with extracorporeal depletion and eﬀective to raise
the absorbed dose to the tumor without increasing side eﬀects,
and it is thereby compatible with any other treatment strategies
such as chemotherapy, radiosensitizers, or fractionated RIT. To
further improve the therapeutic outcomes, investigations of the
optimum combination of treatment strategies would be the
objective of the future research.
In spite of the therapeutic beneﬁt of pretargeting RIT with
avidin−biotin system, it has received little attention due to the
immunogenicity of streptavidin.41 Contrary to the pretargeting
RIT, severe allergic reaction would not be expected in the
avidin chase strategy because avidin is injected only one time,
yet immunogenicity of avidin is still a subject of concern for
clinical use. Some chemical or genetical modiﬁcation of avidin,
or the use of other type of avidin derived from diﬀerent species,
may eventually eliminate the concern related to the
immunogenicity.42,43
There were some limitations in this study. First, we used only
one cell line. Although the use of other cell lines would aﬀect
the therapeutic eﬀect, it would be irrelevant to the blood
clearance acceleration eﬀect and the tumor absorbed dose
enhancement eﬀect of the avidin chase. Therefore, this strategy
has great potential to improve the therapeutic eﬀect of BV-RIT
for any type of VEGF-expressing tumors. Second, further
optimization such as the dose and timing of the avidin injection
is necessary to apply this method in clinical practice. However,
considering its simplicity compared with the conventional
pretargeting strategies, clinical applications of the avidin chase
would be more feasible.
■ CONCLUSION
The avidin chase successfully accelerated the blood clearance of
111In-labeled biotinylated-bevacizumab without impairing its
tumor accumulation level. This strategy also increased the
MTD of 90Y-bevacizumab, and consequently improved the
therapeutic eﬀect. These results underscored the potential
usefulness of 90Y-bevacizumab RIT with the avidin chase for the
treatment of VEGF-positive tumors.
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SUPPORTING INFORMATION 
 
 
 
 
Figure S1. The biodistribution of radioactivity 72 h after the injection of 
111
In-BV 
with different amounts of unlabeled antibody (20, 100, or 500 μg/mouse) in the 
tumor-bearing mice. The tumor accumulation level of 
111
In-BV was significantly 
decreased in a dose-dependent manner (*p<0.05, #p<0.01). The biodistribution study 
data are mean ± SD (n>4). 
  
  
Figure S2. Microscopy images (×40) of an MDA-MB-231 tumor frozen section stained 
with anti-VEGF antibody.  
  
  
Figure S3. The biodistribution of radioactivity after the injection of 
111
In-NuB2 in the 
tumor-bearing mice. The tumor accumulation levels of 
111
In-NuB2 were significantly 
lower than those of 
111
In-BV (*p<0.05). The biodistribution study data are mean ± SD 
(n>4). 
